

## Typhoid vaccine development with a human challenge model



Experimental human typhoid fever challenge was first described in 1896 by Wright, who vaccinated two men against typhoid fever and challenged one with what was then known as *Salmonella typhosa*.<sup>1</sup> While challenge models are sometimes controversial, they offer enormous potential to study the pathogenesis of disease and to accelerate vaccine development, particularly in human-restricted pathogens such as *Salmonella enterica* serovar Typhi. The Maryland typhoid human challenge model, which ran from 1952 to 1974, led to insights into typhoid fever and facilitated the development of live attenuated typhoid vaccine Ty21a.<sup>2,3</sup> A 21st-century typhoid challenge model has been developed by the Oxford Vaccine Group.<sup>4</sup>


In *The Lancet*, Celina Jin and colleagues<sup>5</sup> report results from challenging three groups of healthy adults from Oxford, UK, who were randomly assigned to receive Vi-conjugate vaccine, unconjugated Vi-polysaccharide vaccine, or control vaccine (ACYW135 meningococcal conjugate) with wild-type Quail strain *Salmonella* Typhi. Results of this volunteer challenge have been awaited with much anticipation by the public health community interested in control of typhoid fever in endemic areas of south Asia and sub-Saharan Africa where *S* Typhi is increasingly antibiotic resistant and few treatment options remain. Vi-conjugate vaccines that have been in development represent a new instrument to help to control typhoid. The most advanced conjugate vaccine, Typbar-TCV (Vi-polysaccharide [Vi-PS] conjugated to tetanus toxoid, Vi-TT, Bharat Biotech, Hyderabad, India), is licensed in India where it has been shown to elicit robust serum Vi antibody responses after only one dose, even in Indian infants as young as 6 months.<sup>6</sup> In toddlers, older children, and adults, Typbar-TCV was shown to be significantly more immunogenic than the unconjugated Bharat Vi-PS.<sup>6</sup> Bharat Biotech has submitted an application to WHO for pre-qualification of their Vi-TT. If approved, this would allow the vaccine to be procured by UN agencies. However, despite evidence of safety and immunogenicity in Indian children and adults, heretofore, there has been no evidence of actual efficacy of the vaccine in diminishing the attack rate of typhoid fever upon exposure to virulent *S* Typhi compared with the control participants. Importantly, the authors provide the first data documenting that Typbar-TCV is protective.

112 participants were enrolled in this observer and participant-blinded, randomised controlled trial, which showed that the Vi-TT is well tolerated, achieved 100% seroconversion of Vi antibody (versus 89% for Vi-PS), and stimulated significantly higher geometric mean titres than did unconjugated Vi-PS. Most importantly, Jin and colleagues document that Vi-TT recipients had a significantly lower attack rate for the primary aim endpoint diagnosing typhoid fever than control recipients. With the primary endpoint used in this ambitious trial, the attack rate for typhoid diagnosis was 24 (77%) of 31 in control participants, 13 (35%) of 37 in Vi-TT recipients, and 13 (35%) of 35 in those who received Vi-PS. This translates into vaccine efficacies of 54.6% (95% CI 26.8–71.8) for Vi-TT and 52.0% (23.2–70.0) for Vi-PS.

As the authors suggest, the field efficacy of Vi-TT vaccine might be higher; for example, a well designed and executed field trial of an unlicensed Vi-conjugate produced by the National Institutes of Health (Bethesda, MD, USA) in Vietnamese pre-school children showed an efficacy of 89% (95% CI 76–97) over 46 months of follow-up.<sup>7</sup> One possible explanation lies in the primary endpoint of so-called typhoid infection used by Jin and colleagues<sup>5</sup> (persistent fever  $\geq 38^{\circ}\text{C}$  for  $\geq 12$  h or *S* Typhi bacteraemia), which arguably is better suited to studying typhoid pathogenesis than assessing the efficacy of typhoid vaccines. Using slightly different endpoints such as fever  $38^{\circ}\text{C}$  or higher followed by a positive blood

Published Online  
September 28, 2017  
[http://dx.doi.org/10.1016/S0140-6736\(17\)32407-8](http://dx.doi.org/10.1016/S0140-6736(17)32407-8)

See Online/Articles  
[http://dx.doi.org/10.1016/S0140-6736\(17\)32149-9](http://dx.doi.org/10.1016/S0140-6736(17)32149-9)



Steve Gschmeissner/Science Photo Library

culture, similar to surveillance in a field trial and to endpoints used in the Maryland challenge model, Jin and colleagues<sup>5</sup> report that the efficacy of Vi-TT was 87·1% (95% CI 47·2–96·9), while efficacy of Vi-PS was 52·3% (–4·2 to 78·2). Although future typhoid challenges based on this as a co-primary endpoint would require larger sample sizes, the information gained might be more relevant and predictive of the efficacy that might be noted in a randomised controlled field trial. This highlights the need for the phase 3 and 4 trials, the first of which is expected to be initiated in Asia in late 2017 by the Typhoid Vaccine Acceleration Consortium (TyVAC), a partnership between the University of Maryland, the University of Oxford, and PATH funded by the Bill & Melinda Gates Foundation. However, because it will be some years before these field trials are reported, Jin and colleagues' challenge study results are timely and engender optimism that an effective new instrument has become available to help to control typhoid in hyperendemic populations.

\**Nicholas A Feasey, Myron M Levine*

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK (NAF); and Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA (MML)  
 nicholas.feasey@lstmed.ac.uk

NAF declares no competing interests. MML reports co-developing, with colleagues, a *Salmonella* Enteritidis/*Salmonella* Typhimurium/*Salmonella* Typhi Vi trivalent conjugate vaccine against invasive *Salmonella* disease in sub-Saharan Africa with Bharat Biotech International as a partner and funding from a Strategic Translation Award from the Wellcome Trust. MML has a US patent, 9011871, issued April 21, 2016, for Broad Spectrum Vaccine Against Typhoidal and non-typhoidal *Salmonella* disease, for which MML along with James E Galen, Raphael Simon, and Sharon Tennant are inventors.

Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

- 1 Wright AE. On the association of serous haemorrhages with conditions of defective blood-coagulability. *Lancet* 1896; **2**: 807–09.
- 2 Waddington CS, Darton TC, Woodward WE, Angus B, Levine MM, Pollard AJ. Advancing the management and control of typhoid fever: a review of the historical role of human challenge studies. *J Infect* 2014; **68**: 405–18.
- 3 Gilman RH, Hornick RB, Woodard WE, et al. Evaluation of a UDP-glucose-4-epimeraseless mutant of *Salmonella* Typhi as a liver oral vaccine. *J Infect Dis* 1977; **136**: 717–23.
- 4 Waddington CS, Darton TC, Jones C, et al. An outpatient, ambulant-design, controlled human infection model using escalating doses of *Salmonella* Typhi challenge delivered in sodium bicarbonate solution. *Clin Infect Dis* 2014; **58**: 1230–40.
- 5 Jin C, Gibani MM, Moore M, et al. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of *Salmonella* Typhi: a randomised controlled, phase 2b trial. *Lancet* 2017; published online Sept 28. [http://dx.doi.org/10.1016/S0140-6736\(17\)32149-9](http://dx.doi.org/10.1016/S0140-6736(17)32149-9).
- 6 Mohan VK, Varanasi V, Singh A, et al. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. *Clin Infect Dis* 2015; **61**: 393–402.
- 7 Mai NL, Phan VB, Vo AH, et al. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. *N Engl J Med* 2003; **349**: 1390–91.